Breakthrough Clinical Results
Rapport Therapeutics will release topline data from its Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures on September 8, 2025. RAP-219 is a small molecule precision medicine targeting receptor-associated proteins (RAPs) in the brain. The company is developing RAP-219 for several neurological and psychiatric disorders, including drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain. This announcement highlights the progress of Rapport's lead investigational drug and its potential impact on patients with epilepsy.
Key Highlights
- Topline results from the Phase 2a trial of RAP-219 in drug-resistant focal onset seizures will be announced on September 8, 2025.
- RAP-219 is a small molecule precision medicine targeting receptor-associated proteins (RAPs) in the brain.
- Rapport Therapeutics is developing RAP-219 for several neurological and psychiatric disorders.
- The company's RAP technology platform enables a differentiated approach to neurology drug discovery.
Incidence and Prevalence
Global Incidence and Prevalence of Focal Onset Seizures
After thorough examination of the available literature, there appears to be a significant gap in comprehensive global epidemiological data specifically addressing focal onset seizures. Current research does not provide definitive worldwide statistics on the incidence and prevalence of focal onset seizures as a distinct category.
The literature shows that while focal epilepsy and focal seizures are frequently discussed in clinical contexts related to diagnostic methods, surgical outcomes, and studies of specific patient populations, global epidemiological tracking of these specific seizure types remains limited.
This represents an important area for future epidemiological research, as focal onset seizures (previously called partial seizures) constitute a significant portion of epilepsy cases worldwide. These seizures, which include focal aware seizures (previously simple partial seizures), focal impaired awareness seizures (previously complex partial seizures), and various subtypes such as focal motor, focal sensory, and focal autonomic seizures, would benefit from more dedicated epidemiological study.
The absence of comprehensive global data on incidence rates (new cases per year) and prevalence rates (total existing cases) specifically for focal onset seizures highlights a need for more targeted epidemiological research in this area. Such data would be valuable for healthcare planning, resource allocation, and understanding the true global burden of these specific seizure types.
Researchers and clinicians interested in the epidemiology of focal onset seizures currently must rely on broader epilepsy statistics and regional studies rather than comprehensive global figures specific to focal seizure subtypes.
Drug used in other indications
Clinical Indications and Intervention Models for RAP-219
After a thorough review of available information, there is no data available regarding additional clinical indications for RAP-219 beyond focal onset seizures. The investigational compound does not appear in the current research database with information about its clinical trial portfolio.
Similarly, there is no information available regarding the intervention models, study designs, or treatment protocols being utilized in any clinical trials for RAP-219 for indications other than focal onset seizures.
The absence of data prevents a comprehensive analysis of RAP-219's potential applications across different therapeutic areas or the specific methodological approaches being employed in its clinical development program.
For patients and healthcare providers interested in this investigational treatment, it would be advisable to consult official clinical trial registries or contact the developing pharmaceutical company directly for the most current information on RAP-219's development status and clinical trial program.